New York State Common Retirement Fund Reduces Stock Holdings in DaVita Inc. (NYSE:DVA)

New York State Common Retirement Fund trimmed its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 7.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,354 shares of the company's stock after selling 2,500 shares during the period. New York State Common Retirement Fund's holdings in DaVita were worth $4,839,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in DVA. Blue Trust Inc. increased its stake in shares of DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company's stock worth $54,000 after buying an additional 119 shares during the period. Raymond James & Associates increased its stake in shares of DaVita by 93.6% during the third quarter. Raymond James & Associates now owns 31,316 shares of the company's stock worth $5,134,000 after buying an additional 15,138 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of DaVita during the third quarter worth approximately $10,346,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in DaVita by 1.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company's stock valued at $776,000 after purchasing an additional 70 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in DaVita by 8.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 3,482 shares of the company's stock valued at $571,000 after purchasing an additional 269 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of brokerages recently issued reports on DVA. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $166.33.

DaVita Stock Performance

Shares of NYSE DVA traded down $4.47 during mid-day trading on Monday, hitting $143.41. 723,743 shares of the company were exchanged, compared to its average volume of 870,374. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a 50 day simple moving average of $160.66 and a 200-day simple moving average of $158.23. DaVita Inc. has a 1-year low of $124.78 and a 1-year high of $179.60. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.